Bruce I. Sachs - 31 Jan 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
31 Jan 2023
Transactions value $
-$303,444
Form type
4
Filing time
02 Feb 2023, 15:14:45
Previous filing
18 Jan 2023
Next filing
14 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $86.6K +1.2K +2.91% $72.14* 42.4K 31 Jan 2023 Direct
transaction VRTX Common Stock Sale -$390K -1.2K -2.83% $325.01 41.2K 31 Jan 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -1.2K -5.33% $0.00 21.3K 31 Jan 2023 Common Stock 1.2K $72.14 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.
F2 Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $325.01 (range $325.00 to $325.01).
F4 Fully vested.